The global smart pills market was valued at USD 1.0 billion in 2025 and is projected to reach USD 1.3 billion in 2026 and USD 4.1 billion by 2034, growing at a CAGR of 18.90% during the forecast period 2026–2034. According to Polaris Market Research, digital health innovation and diagnostics enabled by ingestible sensors are fueling this expansion. Major players operating in the global market include CapsoVision, Inc., Medisafe, Medtronic, Olympus Corporation, and Otsuka Holdings Co., Ltd.

Smart Pills Market Segmentation at a Glance

The smart pills market is segmented by application, target area, end use, and region. Application categories include capsule endoscopy, targeted drug delivery, and vital sign monitoring, while target areas span the esophagus, small intestine, large intestine, and stomach. End-use categories cover hospitals, diagnostic centers, and others. This structure helps B2B stakeholders evaluate where ingestible sensors and related technologies are gaining clinical traction.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/smart-pills-market

Capsule Endoscopy Anchors Application Demand

The capsule endoscopy segment held the largest share of 46.3% in 2025. This leadership is driven by the growing prevalence of gastrointestinal disorders, including colon cancer, Crohn's disease, and ulcerative colitis, together with an increasing preference for non-invasive diagnostic procedures. According to the Crohn's & Colitis Foundation, approximately 1 in 100 individuals in the United States is affected by inflammatory bowel disease. The report also cites NCBI data showing that digestive diseases caused approximately 2.5 million deaths globally in 2019, a 37.8% increase compared with 1990. Crohn's disease is most frequently diagnosed in adolescents and young adults, typically between the ages of 20 and 30.

By target area, the small intestine segment held the largest share of 44.1% in 2025, supported by the rising prevalence of small intestine disorders such as Crohn's disease and celiac disease.

Minimally Invasive Diagnostic Procedures Accelerate Adoption

Demand for minimally invasive diagnostic procedures remains a central driver for the smart pills market. NCBI data show that the number of minimally invasive procedures in the United States rose 50% between 2000 and 2018, with more than 15 million performed in 2018. Within this shift, capsule endoscopy offers a distinct advantage: patients simply swallow a small capsule containing a tiny camera, eliminating the need to insert a flexible tube through the mouth or rectum. The report notes that this approach enhances patient comfort, reduces the risk of complications, and may gradually replace traditional endoscopy in certain clinical scenarios. Compared with traditional endoscopy, smart pills require no sedation and little to no recovery time, although they offer limited control over viewing areas.

Targeted Drug Delivery and Technology Convergence

The market is also propelled by rising demand for advanced drug delivery systems that enable optimal utilization of active pharmaceutical ingredients, reduced dosage frequency, minimal side effects, and safer carriers. Targeted drug delivery is expected to attract a substantial customer base among chronic disease patients who require precise medication dosing at the targeted site. The integration of innovative drugs, medical devices, and advanced technologies, alongside the miniaturization of integrated circuits, is anticipated to support continued expansion of the smart pills market.

Regional Outlook and Competitive Landscape

Smart pills market north america led the global market with a 40.7% share in 2025, supported by rapid healthcare technology advancement, high adoption of minimally invasive diagnostic technologies, and the increasing prevalence of colorectal cancer and gastrointestinal disorders. The report expects this dominance to persist throughout the forecast period, citing regulatory approvals for new products as an additional factor. According to the World Health Organization, colorectal cancer is the third most common cancer globally. Asia Pacific is projected to register the highest CAGR of 20.6% during the forecast period. Market leaders are pursuing mergers and acquisitions, enhancements to existing devices, promotional initiatives, and technological advancements to strengthen their positions.

Strategic Implications for B2B Stakeholders

With capsule endoscopy commanding the largest application share and targeted drug delivery identified as a significant use case, device manufacturers, hospitals, and diagnostic centers can align their portfolios with demand for minimally invasive diagnostic procedures. Polaris Market Research's full report provides further segment-level and regional detail across the forecast period 2026–2034.

More Trending Latest Reports By Polaris Market Research:

automotive-market

ethylene-market

market-insights-into-top-10-companies-shaping-lv-mv-switchgear-market-in-2025

us-outdoor-power-equipment-market

intelligent-document-processing-market

morocco-bus-market

italy-influencer-marketing-market

panama-online-gambling-market

travel-agency-services-market